Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Satellos Bioscience Inc
T.MSCL
Alternate Symbol(s):
MSCLF
Healthcare
Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this...
process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MSCL)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 17, 2024 5:45pm
Satellos Announces Pricing of US$40M Overnight Marketed Publ
BREAKING NEWS: $MSCLF Satellos Announces Pricing of US$40M Overnight Marketed Public OfferingBASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS
...more
(0)
•••
Ike101
X
View Profile
View Bullboard History
Post by
Ike101
on Dec 16, 2024 8:50pm
More Diltuion?
News today of public offering!
(168)
•••
Larder111
X
View Profile
View Bullboard History
Post by
Larder111
on Dec 11, 2024 10:33am
Wow up up and away!!
Are we going to hit 1.50 today .this is crazy..
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 13, 2024 10:00pm
Satellos Reports Q3 2024 Financial Results and Provides Clin
Breaking News: $MSCLF Satellos Reports Q3 2024 Financial Results and Provides Clinical Update- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five
...more
(3)
•••
BaddPitt
X
View Profile
View Bullboard History
Comment by
BaddPitt
on Nov 05, 2024 10:19am
RE:RE:Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams
Rug pull on horizon. Up on no volume. Bad look.
(103)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Nov 04, 2024 7:53am
RE:Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams
Satellos to Participate in November 2024 Investor Conferences
(41)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Oct 07, 2024 9:52am
Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams
(41)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Sep 28, 2024 8:04pm
Webinar $MSCL CEO Frank Gleeson Oct 3 @ 1PM ET / 10AM PT
Live Webinar - Satellos Bioscience (MSCL) CEO Frank Gleeson and CFO Elizabeth Williams Thursday, October 3rd at 1PM ET / 10AM PT Q&A with Radius Research Register Here - https
...more
(103)
•••
G1945V
X
View Profile
View Bullboard History
Post by
G1945V
on Jul 11, 2024 10:26am
Filing to Commence a Phase 1 Clinical Trial
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
(103)
•••
G1945V
X
View Profile
View Bullboard History
Post by
G1945V
on Jul 02, 2024 7:59am
Preliminary Data Muscle Repair
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy ("DMD") G1945V
(41)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on May 27, 2024 3:53pm
Webinar Recap: $MSCL CEO Frank Gleeson and Radius Research
(41)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on May 21, 2024 11:51am
Webinar $MSCL CEO Frank Gleeson May 23 @ 2PM ET / 11AM PT
Live Webinar - Satellos Bioscience Inc. (MSCL) w/ CEO Frank Gleeson Thursday, May 23rd at 2PM ET / 11AM PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar
...more
(41)
•••
Drambuey
X
View Profile
View Bullboard History
Post by
Drambuey
on Apr 24, 2024 3:10pm
Post deleted SNOWFLAKES MANAGEMENT
So you deleted my post did it hit too close to home SNOWFLAKE MANAGEMENT? Let me get this straight you roll back the stock 20 to one collect $1.4 million in salaries and the stock is trading at
...more
(103)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Apr 24, 2024 7:13am
RE:You want to do what, AGAIN?
"you want to pass a resolution to roll this back again" Where is this coming from? G1945V
(285)
•••
beenthere
X
View Profile
View Bullboard History
Post by
beenthere
on Mar 12, 2024 4:51pm
Sure Glad The Boys Moved To The TSX
Hate to think where we would be without that move!
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.